Abstract
Background The novel coronavirus COVID-19, has caused a worldwide pandemic, impairing several human organs and systems. Whether COVID-19 affects human thyroid function remains unknown.
Methods 84 hospitalized COVID-19 patients in the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China) were respectively enrolled in this study. In addition, 91 other patients with pneumonia and 807 healthy subjects were included as controls.
Findings We found that the levels of TT3 and TSH were lower in COVID-19 patients than control groups (p<0·001). Within the group of COVID-19 patients, 61.9% patients (52/84) presented with thyroid function abnormalities. We found a larger proportion of patients in severe condition exhibited thyroid dysfunction than mild/moderate cases (74·6% vs. 23·8%, p < 0·001). Patients with thyroid dysfunction tended to have increased interval time for negative conversion of viral nucleic acid (14·1 ± 9·4 vs. 10·6 ± 8·3 days, p = 0·088). To note, thyroid dysfunction was also associated with decreased lymphocytes (p < 0·001) and increased CRP (p = 0·002). In 7 patients with dynamic changes of thyroid function, we observed the levels of TT3 and TSH gradually increased and reached normal range without thyroid hormone replacement at Day 30 post-admission. The correlation between TT3 and TSH level seemed to be positive rather than negative in the early stage, and gradually turned to be negatively related over time.
Interpretations Thyroid function abnormalities are common in COVID-19 patients, especially in severe cases. This might be caused by virus attack and damage to the thyroid-pituitary axis. Therefore, more attention should be paid to thyroid function during treatment of COVID-19, and close follow-up is also needed after discharge.
Funding This study was supported by Zhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Zhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the cases were obtained with informed consent. The research was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data that support the findings of this report are available from the corresponding author upon request.
